Predictive in vitro methods for characterizing product performance, Case study: Furosemide

Information

  • Research Project
  • 8891728
  • ApplicationId
    8891728
  • Core Project Number
    U01FD005305
  • Full Project Number
    1U01FD005305-01
  • Serial Number
    005305
  • FOA Number
    RFA-FD-14-080
  • Sub Project Id
  • Project Start Date
    9/10/2014 - 12 years ago
  • Project End Date
    9/9/2015 - 11 years ago
  • Program Officer Name
  • Budget Start Date
    9/10/2014 - 12 years ago
  • Budget End Date
    9/9/2015 - 11 years ago
  • Fiscal Year
    2014
  • Support Year
    01
  • Suffix
  • Award Notice Date
    9/10/2014 - 12 years ago

Predictive in vitro methods for characterizing product performance, Case study: Furosemide

Abstract A proposal is submitted for RFA-FD-14-080: Predictive in vitro Methods for Characterizing Product Performance, Case Study: Furosemide. The goal of the proposed work is to investigate the effects of milk and related products (baby formula, Ensure) on in vitro dissolution, and establish a basis to relate such data with in vivo absorption. This is of particular relevance to groups such as pediatric patients. This problem is challenging because some previous studies indicate that milk increases in vitro dissolution, which would likely predict faster and more complete absorption in vivo. There is little data directly relating milk with in vivo absorption, but numerous studies show that food reduces/slows furosemide absorption in vivo, while the presence of milk increases in vitro dissolution rates and might be expected to increase absorption rates. Thus, in vivo effects of milk on bioavailability are not well understood. A number of methods have been employed to study in vitro dissolutions, including sampling methodologies and setups that mimic the GI tract. However, we postulate that two other factors are critically important to understand the effects of milk on dissolution and absorption? identifying how the milk components interact with furosemide, and using a better sampling methodology during in vitro dissolutions that isolates the dissolved, free furosemide concentration (as opposed to furosemide that is bound to casein or taken up in fats or emulsions). One of the goals of this proposal is to identify and characterize interactions between furosemide and components of milk and related products, including the protein casein as well as fats contained in milk. This will include studying possible protein binding, and effects of adding surfactants such as bile salts. Another goal is to use PMD to study interactions of furosemide with these components and subsequent effects on the drug distribution. A third goal is to perform dissolution experiments using PMD for sampling, and relate the dissolution data to the physical and chemical behaviors characterized in this study. The ultimate objective is to use in vitro dissolution data to predict in vivo results, and incorporate the effects of milk and related products into these predictions. Thus, modeling will also be done to relate the furosemide and milk effects and resulting dissolution data, especially as related to the free drug, which corresponds to the absorbable form in vivo. In-house software will be TM developed as needed to supplement commercially available software such as GastroPlus , and in vivo simulations will be performed as appropriate. 1/1

IC Name
FOOD AND DRUG ADMINISTRATION
  • Activity
    U01
  • Administering IC
    FD
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    50000
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
    FDA:50000\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZFD1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PHYSICAL PHARMACEUTICA, LLC
  • Organization Department
  • Organization DUNS
    078537371
  • Organization City
    YONKERS
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    107102810
  • Organization District
    UNITED STATES